-The Business Standard Patients' lobbies cheer ruling on anti-cancer drug Glivec, as affordability and access to life-saving drugs get a leg-up Though the India office here of Swiss pharma giant Novartis wore a gloomy look following the Supreme Court rejection of its Glivec patent application, Indian pharmaceutical companies and patients' associations are in celebration mood. D G Shah, secretary general, The Indian Pharmaceutical Alliance (IPA), comprising leading research-based Indian pharma companies, said,...

-IANS The Supreme Court on Monday dismissed Swiss pharmaceutical chain Novartis AG's petition seeking patent protection for its anti-cancer drug, Glivec (Imatinib mesylate). The apex court bench of Justices Aftab Alam and Ranjana Prakash Desai dismissed with cost Novartis' plea challenging the Intellectual Property Appellate Board's decision declining the plea for patent of the drug that is used in the treatment of chronic myeloid leukaemia and malignant gastrointestinal stromal tumours. The patent...

-Reuters Global drugmakers, battered by recent intellectual property decisions in the country, are girding for a landmark court ruling on Monday with broad consequences for their ability to sell lucrative patented medicines in the country. Supreme Court is due to decide on April 1 whether or not Swiss giant Novartis AG's cancer treatment Glivec deserves a patent in the country. "Big Pharma is nervous because nothing has gone in their favour in the...

-The Times of India In a major setback to special economic zone (SEZ) developers, finance minister P Chidambaram has turned down the commerce department's plea to cut the minimum alternate tax (MAT), which was imposed two years ago. A lower or no tax burden was cited as one of the main drivers for boosting investment in what were until recently duty-free enclaves. The commerce department had made a case for reversing Chidambaram's...

-The Telegraph The National Highways Authority of India has accused the Planning Commission of "inconsistencies in stand", saying they are creating confusion and delaying decisions on its projects. NHAI chairperson R.P. Singh has quoted instances - in a letter to commission member B.K. Chaturvedi - where the Planning Commission had taken a diametrically opposite stand from its earlier position that investors should be allowed to exit from finished projects rather than wait...